Are you Dr. Chakravarthy?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 51 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1 Rwj Place
Meb 384
New Brunswick, NJ 08901Phone+1 732-235-7749Fax+1 314-747-8963- Is this information wrong?
Summary
- Dr. Manu Chakravarthy, MD is an endocrinologist in New Brunswick, New Jersey. He is currently licensed to practice medicine in New Jersey, Missouri, and Pennsylvania.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Endocrinology, Diabetes, and Metabolism, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2001 - 2003
McGovern Medical School at UTHealthClass of 2001
Certifications & Licensure
NJ State Medical License 2009 - 2025
MO State Medical License 2006 - 2016
PA State Medical License 2001 - 2003
Publications & Presentations
PubMed
- Editorial: Mitochondrial Biology and Its Role in Metabolic Diseases.Jochen G Schneider, Effie Tozzo, Manu V Chakravarthy> ;Frontiers in Endocrinology. 2022 Jan 1
- 7 citationsSafety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.Stephen A. Harrison, Seth J. Baum, Nadege Gunn, Ziad Younes, Anita Kohli, Rashmee Patil, Margaret James Koziel, Harinder Chera, Jeff Zhao, Manu V. Chakravarthy> ;The American Journal of Gastroenterology. 2021 Aug 12
- 8 citationsA novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human...Daou Nadine, Andreu Viader, Murat Cokol, Arianna Nitzel, Manu V. Chakravarthy, Raffi Afeyan, Tony Tramontin, Svetlana Marukian, Michael Hamill> ;Scientific Reports. 2021 Jun 4
- Join now to see all
Press Mentions
Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 DiabetesMay 4th, 2021- Carmot Therapeutics Expands Leadership Team with Appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of R&DMarch 17th, 2021
- Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 MilestonesJanuary 11th, 2021
- Join now to see all
Grant Support
- Identification Of The Physiologically Relevant Endogenous Ligand For Ppar?National Center For Research Resources2009–2011
- ?New" Hepatic Fat Activates Ppar? To Maintain Glucose, Lipid, And CholesterolNational Center For Research Resources2007
- New Hepatic Fat Activates Ppara To Maintain Glucose Lipid Cholesterol HomeoNational Center For Research Resources2006–2007
